Terms: = Leukemia AND NTRK3, TRKC, 4916, ENSG00000140538, Q16288, gp145 trkC
44 results:
1. Targeted therapy using larotrectinib and venetoclax for the relapsed/refractory T-cell acute lymphoblastic leukemia harboring a cryptic ETV6-ntrk3 fusion.
Zhou K; Gong D; He C; Xiao M; Zhang M; Huang W
Mol Carcinog; 2023 Jul; 62(7):899-906. PubMed ID: 37036164
[TBL] [Abstract] [Full Text] [Related]
2. Somatic homozygous loss of SH2B3, and a non-Robertsonian translocation t(15;21)(q25.3;q22.1) with ntrk3 rearrangement, in an adolescent with progenitor B-cell acute lymphoblastic leukemia with the iAMP21.
Capela de Matos RR; Othman M; Ferreira GM; Monteso K; de Souza MT; Rouxinol M; Melo JB; Carreira IM; Abdelhay E; Liehr T; Ribeiro RC; Silva M
Cancer Genet; 2022 Apr; 262-263():16-22. PubMed ID: 34974289
[TBL] [Abstract] [Full Text] [Related]
3. Second Report of
Hughes CE; Correa H; Benedetti DJ; Smith B; Sumegi J; Bridge J
Pediatr Dev Pathol; 2021; 24(6):554-558. PubMed ID: 34120511
[TBL] [Abstract] [Full Text] [Related]
4. Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.
Joshi SK; Qian K; Bisson WH; Watanabe-Smith K; Huang A; Bottomly D; Traer E; Tyner JW; McWeeney SK; Davare MA; Druker BJ; Tognon CE
Blood; 2020 Jun; 135(24):2159-2170. PubMed ID: 32315394
[TBL] [Abstract] [Full Text] [Related]
5. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-ntrk3 rearrangement.
Nardi V; Ku N; Frigault MJ; Dubuc AM; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Burke ME; Foster J; Dal Cin P; Maus MV; Fathi AT; Hock H
Blood Adv; 2020 Jan; 4(1):106-111. PubMed ID: 31905241
[TBL] [Abstract] [Full Text] [Related]
6. Larotrectinib in TRK fusion-positive pediatric B-cell acute lymphoblastic leukemia.
Schewe DM; Lenk L; Vogiatzi F; Winterberg D; Rademacher AV; Buchmann S; Henry D; Bergmann AK; Cario G; Cox MC
Blood Adv; 2019 Nov; 3(22):3499-3502. PubMed ID: 31725893
[TBL] [Abstract] [Full Text] [Related]
7. A Case of Papillary Thyroid Carcinoma and Kostmann Syndrome: A Genomic Theranostic Approach for Comprehensive Treatment.
Han S; Ehrhardt J; Shukla S; Elkbuli A; Nikiforov YE; Gulec SA
Am J Case Rep; 2019 Jul; 20():1027-1034. PubMed ID: 31308356
[TBL] [Abstract] [Full Text] [Related]
8. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
[TBL] [Abstract] [Full Text] [Related]
9. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
10. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J; Pavlick D; Yoshimi A; Marcelus C; Chung SS; Hechtman JF; Benayed R; Cocco E; Durham BH; Bitner L; Inoue D; Chung YR; Mullaney K; Watts JM; Diamond EL; Albacker LA; Mughal TI; Ebata K; Tuch BB; Ku N; Scaltriti M; Roshal M; Arcila M; Ali S; Hyman DM; Park JH; Abdel-Wahab O
J Clin Invest; 2018 Aug; 128(9):3819-3825. PubMed ID: 29920189
[TBL] [Abstract] [Full Text] [Related]
11. Insulin-like growth factor 1 receptor stabilizes the ETV6-ntrk3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation.
Tognon CE; Rafn B; Cetinbas NM; Kamura T; Trigo G; Rotblat B; Okumura F; Matsumoto M; Chow C; Davare M; Pollak M; Mayor T; Sorensen PH
J Biol Chem; 2018 Aug; 293(32):12502-12515. PubMed ID: 29903916
[TBL] [Abstract] [Full Text] [Related]
12. Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features.
Zhou F; Chen B
Hematology; 2018 Oct; 23(9):608-612. PubMed ID: 29894279
[TBL] [Abstract] [Full Text] [Related]
13. ETV6-ntrk3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition.
Roberts KG; Janke LJ; Zhao Y; Seth A; Ma J; Finkelstein D; Smith S; Ebata K; Tuch BB; Hunger SP; Mullighan CG
Blood; 2018 Aug; 132(8):861-865. PubMed ID: 29880614
[No Abstract] [Full Text] [Related]
14. Kinase domain activation through gene rearrangement in multiple myeloma.
Morgan GJ; He J; Tytarenko R; Patel P; Stephens OW; Zhong S; Deshpande S; Bauer M; Weinhold N; Schinke C; Rasche L; Bailey M; Ali S; Ross J; Miller VA; Stephens P; Thanendrarajan S; Zangari M; van Rhee F; Mughal T; Davies FE; Walker BA
Leukemia; 2018 Nov; 32(11):2435-2444. PubMed ID: 29654269
[TBL] [Abstract] [Full Text] [Related]
15. Novel identification of STAT1 as a crucial mediator of ETV6-ntrk3-induced tumorigenesis.
Park J; Kim J; Park B; Yang KM; Sun EJ; Tognon CE; Sorensen PH; Kim SJ
Oncogene; 2018 Apr; 37(17):2270-2284. PubMed ID: 29391602
[TBL] [Abstract] [Full Text] [Related]
16. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in
Smith KM; Fagan PC; Pomari E; Germano G; Frasson C; Walsh C; Silverman I; Bonvini P; Li G
Mol Cancer Ther; 2018 Feb; 17(2):455-463. PubMed ID: 29237803
[TBL] [Abstract] [Full Text] [Related]
17. A new ETV6-ntrk3 cell line model reveals MALAT1 as a novel therapeutic target - a short report.
Chen S; Nagel S; Schneider B; Dai H; Geffers R; Kaufmann M; Meyer C; Pommerenke C; Thress KS; Li J; Quentmeier H; Drexler HG; MacLeod RAF
Cell Oncol (Dordr); 2018 Feb; 41(1):93-101. PubMed ID: 29119387
[TBL] [Abstract] [Full Text] [Related]
18. Philadelphia chromosome-like acute lymphoblastic leukemia.
Tasian SK; Loh ML; Hunger SP
Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
[TBL] [Abstract] [Full Text] [Related]
19. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract] [Full Text] [Related]
20. Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.
Nelson KN; Peiris MN; Meyer AN; Siari A; Donoghue DJ
Trends Mol Med; 2017 Jan; 23(1):59-79. PubMed ID: 27988109
[TBL] [Abstract] [Full Text] [Related]
[Next]
